Proxy Fight

  • SINOVAC Board Files Investor Presentation on Protecting Shareholder Interests

    SINOVAC Biotech is urging shareholders to vote against proposals to replace the board, citing its efforts to restore shareholder value, including dividend payments and a strategic realignment. The company launched www.VoteSinovac.com and filed an investor presentation with the SEC, highlighting the board’s commitment to maximize shareholder investment, defend against litigation from a dissenting investor group, and potentially relist on the Hong Kong Stock Exchange.

    2025年6月24日
  • Apollo Capital Warns MediPharm Shareholders of Ongoing Value Erosion and Insolvency Risks Amidst Catastrophic Q1 Financial Performance

    Apollo Capital warns MediPharm Labs (TSX: LABS) faces insolvency within six months, citing a $3.3M Q1 2025 cash burn (double 2024’s rate) and 21 consecutive quarterly losses. The activist shareholder alleges board mismanagement, claiming CEO David Pidduck’s optimistic statements contradict urgent financial collapse risks. Revenue fell 10% globally, with international markets down 18%, while executive stock compensation and unaddressed SG&A costs ($16.2M TTM) masked by “illusory” EBITDA spin exacerbate concerns. Apollo advocates leadership overhaul via shareholder vote, urging rejection of green-themed corporate proxy materials and supporting restructuring candidates with cannabis crisis expertise. Insolvency appears inevitable absent board replacement.

    2025年5月17日